ECEHH appoints new director
Professor Lora Fleming is a leading expert in the environment and public health
Michael Depledge, who has been interim director, will continue in his role as chairman of the advisory board.
Fleming joins ECEHH from the University of Miami where she was a professor in both the medical and marine schools, with particular interests in environmental and occupational health and epidemiology.
She has also held senior roles in the Division of Marine Biology and Fisheries at the Rosenstiel School of Marine and Atmospheric Sciences; the Department of Epidemiology in the Department of Epidemiology and Public Health at the Miller School of Medicine; the University of Miami Oceans and Human Health Center; and the Florida Cancer Data System,.
ECEHH is an initiative of the Peninsula College of Medicine and Dentistry – a joint venture of the University of Exeter and the University of Plymouth in the UK and the NHS in the South West of England – with investment from the ERDF (European Regional Development Fund) Convergence Programme.
ECEHH develops international research to investigate the complex and interactive relationships between the environment and human health. The research takes place within Cornwall from the expanded Knowledge Spa at Treliske and in laboratory-based facilities co-located with the University of Exeter’s Environment and Sustainability Institute, which will be built at Tremough, with collaborations with other research institutions around the world.
The ECEHH focuses on three key themes: the first investigates the effects of chemicals in the environment on human health, including pharmaceuticals and nanomaterials.
The second is climate, oceans and human health. Although the ECEHH looks at climate, oceans and human health globally, it also works on threats in a broader context and of special significance to the coastal communities of Cornwall. These include climate change, the acidification of the oceans and the threat caused by the invasion of species from other regions, such as jellyfish and toxic algae.
The third is clinical photo-biology, and is a continuation and expansion of research already taking place in Cornwall. Research in this area investigates the affects of UV on the skin, and how UVA and pollutants (such as radon and arsenic) interact and influence health.
Fleming said: ‘Our work will help to anticipate and prevent problems, mitigate problems where they do occur, discover new opportunities for businesses, county government and NGOs, and investigate ways in which we can interact with the environment in a positive way.’
You may also like
Manufacturing
etherna's mRNA and LNP platforms advance Dropshot Therapeutics' renal disease programme to clinical stage
etherna has announced that partner Dropshot Therapeutics has validated its platforms in preclinical renal disease research and will now progress to IND-enabling studies, with etherna providing GMP manufacturing support ahead of planned Phase I clinical trials in 2027
Manufacturing
Lonza expands AAV offering with Xcite AAV stable Producer Cell Line platform to idustrialise Viral Vector Manufacturing
New technology demonstrates superior performance versus transient transfection in clinically relevant customer gene of interest and engineered capsid, enabling scalable and cost-effective AAV manufacturing. Launch reflects Lonza’s deep expertise in cell line development, viral vector manufacturing, and platform industrialisation built over decades of supporting complex biologics
Manufacturing
Piramal Pharma Solutions unveils state-of-the-art payload-linker suite at its Riverview, Michigan facility
The Riverview facility provides comprehensive services for active pharmaceutical ingredients (APIs) and high potency APIs (HPAPIs), including specialised solutions for payload-linkers. This cutting-edge suite will significantly enhance the company’s ability to support global payload-linker development and manufacturing and help partners bring complex therapies like antibody-drug conjugates (ADCs) and other bioconjugates to market
Research & Development
VoxCell BioInnovation and adMare partner to validate bioprinted vascularised cancer tissue models for antibody therapy development
The pair have announced a research collaboration using VoxCell's human-relevant bioprinted vascularised cancer tissue models to validate a novel antibody-based immune-modulating therapy, as the FDA advances plans to reduce animal testing for monoclonal antibodies through New Approach Methodologies
Research & Development
Brainomix and Boehringer Ingelheim continue partnership in pulmonary fibrosis
The pair will advance their strategic partnership to the next phase of clinical trials for Brainomix's e-Lung after strong initial results demonstrated its potential to enable earlier diagnosis of progressive pulmonary fibrosis